6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2003
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 24 October, 2003 By Ronald Lea Erratt, Company secretary

ASX & MEDIA RELEASE
24 October, 2003
CHAIRMAN'S ADDRESS AT THE ANNUAL GENERAL MEETING

1 Company achievements over the past year.
In the letter to all shareholders sent by the Managing Director
which accompanied the annual accounts, there were listed many
of the extensive public announcements that the Company has made
this year.
A review of that list alone, quantifies the scope of
the significant advances we have made over each of our
therapeutic areas.

In the anti-cancer area alone we have announced the achievement
of seven milestones between July 2002 and June 2003. The
details of the scientific developments and clinical strategy
that underpin these advances will be the subject of the
presentation by the program director, Dr Graham Kelly.

In the other areas of technology development, the announcements
of our achievements have been equally prolific. We have
notified our shareholders of our progress at the rate of on
average of an update every three weeks, and this does not
include the procedural statements we are obliged to make from
time to time. The number of announcements is not of itself
definitive of importance until you look at the quality of
the achievements described. And in this regard our last
year has been most notable, and the announcement schedule
has recorded exciting advances in every area of the business.

On the corporate front, we have had success by public
recognition of our Export activities as joint winners
of the Australian Technology Showcase Award, through to
an event not announced directly by the Company, but
notable nevertheless, in being the 2002/3 best share
price performer of the top 200 companies on the
Australian Stock Exchange.

On the intellectual property front, in the year under
review we have had patents granted in the US and Australia
covering our anti-inflammatory program NV-07a, and two US
patents covering our Consumer product portfolio. Advances
in our intellectual property continue, with more patents
applied for during the year. Although patent costs form
a significant part of the our R&D budget, we continue to
regard our patents, our confidential know-how, and our
staff, as the real value within the Company which underpins
the strategic developments we have planned for the years ahead.

2. Review of the technology - therapeutic areas
- - OTC - Glycotex.

Our clinical trial programs have expanded this year and
particularly the phase II trials with phenoxodiol,
which are being conducted through Marshall Edwards Inc.
In the other areas, we have completed our clinical trials
program in the topical skin anti-inflammatory, we are
continuing the program in the cardiovascular area, and
our subsidiary company Glycotex, Inc., has commenced
trials with the Glucoprime compound for skin ulcer repair.
The worldwide OTC business has reorganised its operations
to come into line with our stated strategy of conserving
cash and reducing expenditures to improve financial performance.
Despite the growth in our R&D expenditures and the
expedition of our clinical activities, we have managed as
a group to improve year-end financial results and finish
the year in a strong cash position.

3. New Directors

The Board was very pleased to secure the services of
Professor Leanna Read as a non-executive Director.
Apart from impressive academic qualifications she has
received 2 eminent awards for services to the
biotechnology industry, is a member of the Prime Minister's
Innovation and Engineering Council and is CEO of a
biotechnology company. Prof Read adds a mixture o
f biotechnology, technical and management experience
to an already very competent Board.

Our subsidiary company Marshall Edwards. Inc., also added
a new non-executive Director this year in Mr Stephen Breckenridge.
Mr Breckenridge brings to the group many years of financial
experience and a detailed knowledge of the financial
realities of the global pharmaceutical industry.

These appointments demonstrate our continued commitment
to appointing Directors with the skills and experience
directly applicable to the development and oversight
needs of Novogen and Marshall Edwards.

4. Share ownership and geography
Novogens share activity on the Nasdaq National Market
in the US is continuing to demonstrate the
wisdom of the early and gradual introduction of the
Company stock to the US market that has been taking
place over the last four years. Although the Company
has not directly issued any stock on the US market, the
trading of the Company stock on Nasdaq now represents
such a significant proportion of trading that the
question as to whether the ASX or the Nasdaq is the dominant
exchange is now open for debate. Over 28% of the
Company shares are held in American Deposit Receipt
form on the Nasdaq market, and it is estimated
that US interests hold more that half of the
Company through direct ASX holdings or through the
ADR program on Nasdaq. We expect the trend to US
ownership to continue while the Company remains
relatively undervalued in US terms.
We are confident that the trend of the local market
in gradually coming to understand that the Novogen
group is still undervalued will also accelerate in
the near future.
5. The year ahead

We are planning for an exciting 2004.
The oncology program, about which you will hear
more shortly, has proceeded to a point where we are
confident we can coordinate the trial result schedule
with the regulatory requirements for expedited
product registration. Also we are very excited by the
follow-on compounds to phenoxodiol which offer the
Novogen group a pipeline of anti-cancer drugs that
could reshape the oncology prescription drug landscape.
Each of our other technical areas is equally as
exciting and promising.
Our financial position is solid, our portfolio is
developing and expanding rapidly, our management is
talented and focused, and with the continued support
of our shareholders we expect to reward that support
with significant capital growth.
Additionally and equally as importantly, we intend
o provide safer drug therapy and measurable benefits
to the patients who currently suffer from an absence
of adequate therapy.

Philip Johnston
Chairman
Novogen Limited
24 October, 2003

More information on the Company can be found at
www.novogen.com.

ISSUED FOR : NOVOGEN LIMITED
LISTINGS : ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION : RON ERRATT,
COMPANY SECRETARY, NOVOGEN LIMITED TEL +61 2 9878 0088